Investor Sues Drug Company, Others Over Clinical Test Result Misrepresentations

Mealey's (June 17, 2016, 1:46 PM EDT) -- NEWARK, N.J. — A shareholder filed a securities class action complaint in New Jersey federal court on June 9, alleging that a pharmaceutical company and certain of its executive officers misrepresented the clinical test results for a cancer treatment drug the company was developing in violation of federal securities laws (Jessica Fergus v. Immunomedics Inc., et al., No. 16-3335, D. N.J.).

(Fergus complaint available. Document #57-160620-511C.)

Shareholder Jessica Fergus filed the complaint in the U.S. District Court for the District of New Jersey on behalf of...
To view the full article, register now.